Financial PositionABCL is leveraging its large $800M+ liquidity position to cultivate an internal pipeline and high-value strategic partnerships.
R&D And Pipeline DevelopmentAbCellera is focusing on its two leading internal R&D programs, ABCL635 in the metabolic and endocrinology medical area and ABCL575, targeting immunology and inflammation.
Strategic PartnershipsAbCellera succeeded in signing two new partnerships in 2024, with Biogen and venture firms Viking and ArrowMark, and expanding two legacy programs.